Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026
Incyte to present 30+ ASH 2026 abstracts, including INCA033989 myelofibrosis and ET data and latarcibart VWD results, plus an investor…
What this release says
Incyte says more than 30 abstracts on its hematology portfolio will be presented at the 2026 ASH Annual Meeting in New Orleans, including new data on INCA033989 in myelofibrosis and essential thrombocythemia and long-term data on latarcibart in von Willebrand disease. For a shareholder, this is a scheduled set of data updates from early-stage programs, not a commercial or financial event.
Key figures
- Abstracts to be presented
- More than 30
- Investor event date
- December 12, 2026
Positive for shareholders
- Incyte plans an investor event and webcast to discuss the data.
- Latarcibart has received Breakthrough Therapy and Fast Track designations from the FDA.
Negative for shareholders
- Most of the featured programs are investigational and their results are preliminary.
- INCA033989 data are from Phase 1 studies, which are early in the development process.
Written by Quantisnow AI from this release. Not financial advice.
Key terms
- Myelofibrosis (MF):
- A rare bone marrow disease in which scar tissue forms and blood cell production is disrupted.
- Essential thrombocythemia (ET):
- A rare blood disorder in which the body makes too many platelets.
- Von Willebrand disease (VWD):
- An inherited bleeding disorder caused by a shortage or defect of a clotting protein called von Willebrand factor.
- Prophylaxis:
- Treatment given regularly to prevent an event, such as bleeding, rather than to treat it after it occurs.
FAQ
When will Incyte present its new ASH data?
The presentations are scheduled during the 2026 ASH Annual Meeting, held December 12 to 15, 2026, in New Orleans.
When is Incyte's investor event on the ASH data?
Incyte will host an investor event and webcast on Saturday, December 12, 2026, from 7:30 to 9:00 p.m. CT.
Historical context for INCY
Across the 27 sessions after earlier INCY headlines, the stock closed higher 11 times and lower 16 times, with a median move of 1.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | INCY | SPY |
|---|---|---|---|
| Nov 4, 2026 | Incyte to Present at Upcoming Investor Conferences | +4.5% | +1.7% |
| Oct 30, 2026 | Incyte upgraded by Oppenheimer with a new price target | +3.1% | -1.8% |
| Oct 29, 2026 | Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates | -0.1% | -0.4% |
| Oct 26, 2026 | Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026 | -2.1% | +0.7% |
| Oct 20, 2026 | Morgan Stanley resumed coverage on Incyte with a new price target | +3.0% | +0.3% |
| Oct 19, 2026 | Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 | +0.2% | +0.4% |
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
Follow INCY and get a push notification the moment its next story breaks.